Advanced MRI Applications Development
- Conditions
- Brain Tumors
- Registration Number
- NCT01847833
- Lead Sponsor
- Massachusetts General Hospital
- Brief Summary
The goals of this study are to:
1. To improve upon and develop new innovative magnetic resonance imaging techniques that refine image quality and enhance performance. Improvements in these areas will have positive implications for medical diagnosis and treatment.
2. To correlate MRI images with underlying disease pathophysiology in order to ensure that imaging accurately reflects the disease process.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Brain Tumor
Exclusion Criteria
- Unable to undergo MRI
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method patients alive and progression free at 6 months 6 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular biomarkers are being evaluated in NCT01847833 for brain tumor characterization using advanced MRI techniques?
How do advanced MRI methods in NCT01847833 correlate with glioblastoma multiforme pathophysiology compared to standard imaging protocols?
What are the potential adverse events associated with novel MRI contrast agents used in the NCT01847833 observational brain tumor study?
Are there any combination imaging approaches with molecular targeting therapies being explored in NCT01847833 for meningioma or medulloblastoma subtypes?
How does the NCT01847833 trial at Massachusetts General Hospital advance quantitative MRI metrics for brain tumor treatment monitoring?
Trial Locations
- Locations (1)
MGH
🇺🇸Boston, Massachusetts, United States
MGH🇺🇸Boston, Massachusetts, United StatesElizabeth GerstnerPrincipal Investigator